Skip to main content
Home
Latest news
Browse topics
Cardiovascular disorders Chronic kidney disease Diabetes devices & technology GLP-1 receptor agonists Hyperglycemia Hypoglycemia Obesity, diet, & lifestyle interventions SGLT2 inhibitors Type 1 diabetes Type 2 diabetes Browse all topics
EN
EN
In focus
Novel clinical evidence in continuous glucose monitoring Fasting for religion and health in people with diabetes The challenge of type 2 diabetes in children HFpEF & diabetes: Diagnosis and management in the wake of EMPEROR-Preserved Addressing suicide risk in diabetes: Rates and risk factors, HCP fears, and practical advice The SURPASS trials: Summarizing efficacy data on tirzepatide Semaglutide for weight loss: STEP and SELECT trials: Results from the STEP and SELECT trials Why psychosocial care matters DiRECT: Type 2 diabetes remission through weight management
Congress coverage
EASD 58th Annual Meeting 2022 The American Diabetes Association 82nd Scientific Sessions
About us
Medicine Matters Diabetes
EXTENDED SEARCH

The American Diabetes Association 82nd Scientific Sessions

ADA 2022 highlights

06-07-2022 | ADA 2022 | Conference coverage | News

​​​​​​​ADA/KDIGO consensus: ‘Speaking the same language’ on CKD management

The ADA and KDIGO have produced a consensus statement on treating chronic kidney disease in people with diabetes.

06-06-2022 | ADA 2022 | Conference coverage | News

Annual wellness check may reduce amputation likelihood in high-risk locales

People with diabetes who attend an annual wellness check are significantly less likely to require a major lower extremity amputation within the same year, shows research from the US Diabetes Belt.

06-04-2022 | ADA 2022 | Conference coverage | News

​​​​​​​SURMOUNT-1 places tirzepatide weight loss efficacy within surgical range

A weekly injection of tirzepatide results in a substantial bodyweight reduction over and above that achieved with lifestyle intervention in people with obesity, show the SURMOUNT-1 findings.

06-04-2022 | ADA 2022 | Conference coverage | Video

SURMOUNT-1: Heralding a ‘golden age’ for obesity treatment

Louis Aronne discusses the results of SURMOUNT-1, and why he believes they may represent the start of a major shift in the treatment of people with obesity.

ADA 2022 research news

CKD and type 2 diabetes combined conveys greatest vascular risk in people with CVD

06-08-2022 ADA 2022 News

First-in-class glucokinase activator dorzagliatin could help treat some GK-MODY patients

06-08-2022 ADA 2022 News

OpenAPS closed-loop algorithm improves glucose control in formal trial

06-08-2022 ADA 2022 News

Overnight glycemic variability may impact next day function

06-08-2022 ADA 2022 News

Stem cell approach shows promise for unstable type 1 diabetes

06-07-2022 ADA 2022 News

​​​​​​​Artificial intelligence platform shows promise for type 2 diabetes remission

06-07-2022 ADA 2022 News

Case series suggests SGLT2 inhibitors could be useful add-on therapy for MODY3

06-07-2022 ADA 2022 News

Increased time in range using FreeStyle Libre improves multiple diabetes outcomes

06-06-2022 ADA 2022 News

​​​​​​​Hypoglycemia risk from insulin overdose no worse with icodec than glargine

06-06-2022 ADA 2022 News

Sexual dysfunction common in individuals with prediabetes and type 2 diabetes

06-06-2022 ADA 2022 News

Women most often have psychosocial consequences of hypoglycemia

06-06-2022 ADA 2022 News

Psychosocial factors predict poor medication adherence in young people with type 2 diabetes

06-06-2022 ADA 2022 News
More research news from ADA 2022

Vitamin B12 monitoring rare despite metformin prescription

06-05-2022 ADA 2022 News

Almost any liver fat may be abnormal

06-05-2022 ADA 2022 News

Success of Omnipod 5 closed-loop system in preschoolers continues at 1 year

06-05-2022 ADA 2022 News

​​​​​​​Ultra-rapid lispro noninferior to standard version in children

06-05-2022 ADA 2022 News

Renal benefits of tirzepatide revealed

06-05-2022 ADA 2022 News

Bionic pancreas removes math from diabetes

06-04-2022 ADA 2022 News

Adolescent obesity may trigger type 1 diabetes

06-04-2022 ADA 2022 News

AWARD-PEDS: Dulaglutide improves glycemic control for youths with type 2 diabetes

06-04-2022 ADA 2022 News


Medicine Matters conference coverage is brought to you in partnership with medwireNews


Image Credits